Advertisement

Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease

  • Chase S. CorreiaEmail author
  • Melissa R. Briones
  • Rong Guo
  • Rochella A. Ostrowski
Brief Report
  • 69 Downloads

Abstract

This paper is to examine the relationship between anti-cyclic citrullinated peptide (anti-CCP) antibody titers and the development of interstitial lung disease (ILD) in patients with and without rheumatoid arthritis (RA). A retrospective investigation was conducted on all adult patients tested for anti-CCP between January 1, 2007, and December 31, 2012, in a university healthcare system. Patients with specified exposures or conditions known to cause ILD were excluded. The prevalence of ILD was compared between those with and without a positive CCP. The study population was then divided into four titer groups based on anti-CCP titers: negative, low titer, moderate titer, high titer. Fisher’s exact tests compared the prevalence of ILD among the anti-CCP titer groups. Multivariate logistic regression examined the association between anti-CCP and ILD while controlling for confounders. These analyses were repeated in two subgroups: a “confirmed RA” subgroup and an “unconfirmed RA” subgroup. Two thousand and thirty patients met inclusion criteria and 453 of those had confirmed RA. Progressively higher anti-CCP titer groups developed an increasingly higher prevalence of ILD (p < 0.01). When adjusting for age, tobacco, and a diagnosis of RA, higher anti-CCP titer groups continued to correlate with an increased prevalence of ILD (OR 1.47, 95% CI 1.10–1.96, p < 0.001). This study is the first to show that progressively higher anti-CCP titers correlate with increasing prevalence of ILD, even when adjusting for confounders.

Keywords

Interstitial lung disease (ILD) Rheumatoid arthritis (RA) Rheumatology 

Notes

Compliance with ethical standards

Disclosures

None.

References

  1. 1.
    Shah AS (2012) Rheumatoid arthritis. In: Longo DE (ed) Harrison’s Principles of Internal Medicine 18th edition. McGraw-Hill, New York, p 2739Google Scholar
  2. 2.
    Kelly C et al (2014) Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics - a large multicentre UK study. Rheumatology 53:1676–1682CrossRefGoogle Scholar
  3. 3.
    Bongartz T et al (2010) Incidence and mortality of interstitial lung disease in rheumatoid arthritis. Arthritis Rheumatol 62(6):1583–1591CrossRefGoogle Scholar
  4. 4.
    Kim EJ, H C (2009) Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 5(136):1397–1405CrossRefGoogle Scholar
  5. 5.
    Inui N et al (2008) Anti-cyclic citrullinated peptide antibodies in diseases associated with rheumatoid arthritis. Clin Biochem 41:1075–1077CrossRefGoogle Scholar
  6. 6.
    Chen J et al (2015) Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 67(1):28–38CrossRefGoogle Scholar
  7. 7.
    Giles JT et al (2013) Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum DisGoogle Scholar
  8. 8.
    Alexious I et al (2008) Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol 27:511–513CrossRefGoogle Scholar
  9. 9.
    Bieber V et al (2013) Autoimmune smoke and fire--coexisting rheumatoid arthritis and chronic obstructive pulmonary disease: a cross-sectional analysis. Immunol Res 56(2–3):261–266CrossRefGoogle Scholar
  10. 10.
    Dagan A et al (2017) Coexistent malignant conditions in rheumatoid arthritis - a population-based cross-sectional study. Int J Clin Pract 71:e12929CrossRefGoogle Scholar
  11. 11.
    Aletaha D et al (2010) 2010 Rheumatoid arthritis classification criteria. Arthritis Rheumatol 62(9):2569–2581CrossRefGoogle Scholar
  12. 12.
    Mori S et al (2012) Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med 106(11):1591–1599CrossRefGoogle Scholar
  13. 13.
    Linn- Rasker SP et al (2006) Smoking is a risk factor for anti- CCP antibodies only in rheumatoid arthritis patients who carry HLA- DRB1 shared epitope alleles. Ann Rheum Dis 3(65):366–371CrossRefGoogle Scholar
  14. 14.
    Vassallo RRJ (2012) Smoking-related interstitial lung diseases. Clin Chest Med 33:165–178CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  1. 1.Division of RheumatologyNorthwestern Memorial HospitalChicagoUSA
  2. 2.Division of Allergy, Immunology, and RheumatologyLoyola University Medical CenterMaywoodUSA
  3. 3.Department of Medicine Statistics CoreUniversity of CaliforniaLos AngelesUSA

Personalised recommendations